

**PHARMACEUTICAL DOSAGE FORMS**

5           **[001]** This application claims priority from U.S. Provisional Application Serial  
                  No. 60/840,244, filed August 25, 2006, the disclosure of which is hereby  
                  incorporated by reference.

**TECHNICAL FIELD OF THE INVENTION**

10           **[002]** The present invention relates to pharmaceutical dosage forms, for  
                  example to a tamper resistant dosage form including an opioid analgesic, and  
                  processes of manufacture, uses, and methods of treatment thereof.

**BACKGROUND OF THE INVENTION**

15           **[003]** Pharmaceutical products are sometimes the subject of abuse. For  
                  example, a particular dose of opioid agonist may be more potent when  
                  administered parenterally as compared to the same dose administered orally.  
                  Some formulations can be tampered with to provide the opioid agonist  
20            contained therein for illicit use. Controlled release opioid agonist  
                  formulations are sometimes crushed, or subject to extraction with solvents  
                  (e.g., ethanol) by drug abusers to provide the opioid contained therein for  
                  immediate release upon oral or parenteral administration.

25           **[004]** Controlled release opioid agonist dosage forms which can liberate a  
                  portion of the opioid upon exposure to ethanol, can also result in a patient  
                  receiving the dose more rapidly than intended if a patient disregards  
                  instructions for use and concomitantly uses alcohol with the dosage form.

30           **[005]** There continues to exist a need in the art for pharmaceutical oral dosage  
                  forms comprising an opioid agonist without significantly changed opioid

release properties when in contact with alcohol and/or with resistance to crushing.

### OBJECTS AND SUMMARY OF THE INVENTION

5

[006] It is an object of certain embodiments of the present invention to provide an oral extended release dosage form comprising an active agent such as an opioid analgesic which is tamper resistant.

10

[007] It is an object of certain embodiments of the present invention to provide an oral extended release dosage form comprising an active agent such as an opioid analgesic which is resistant to crushing.

15

[008] It is an object of certain embodiments of the present invention to provide an oral extended release dosage form comprising an active agent such as an opioid analgesic which is resistant to alcohol extraction and dose dumping when concomitantly used with or in contact with alcohol.

20

[009] In certain embodiments, the present invention is directed to a solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation in the form of a tablet or multi particulates, wherein the tablet or the individual multi particulates can be at least flattened without breaking, characterized by a thickness of the tablet or of the individual multi particulate after the flattening which corresponds to no more than about 60 % of the thickness of the tablet or the individual multi particulate before flattening, and wherein said flattened tablet or the flattened multi particulates provide an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active released at 0.5 hours of dissolution that deviates no more than about 20 % points from the

30

corresponding in-vitro dissolution rate of a non-flattened reference tablet or reference multi particulates.

5 [0010] In certain embodiments, the present invention is directed to a solid oral  
extended release pharmaceutical dosage form comprising an extended release  
matrix formulation in the form of a tablet or multi particulates, wherein the  
tablet or the individual multi particulates can at least be flattened without  
breaking, characterized by a thickness of the tablet or the individual multi  
10 particulate after the flattening which corresponds to no more than about 60%  
of the thickness of the tablet or the individual multi particulate before  
flattening, and wherein the flattened or non flattened tablet or the flattened or  
non flattened multi particulates provide an in-vitro dissolution rate, when  
measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated  
15 gastric fluid without enzymes (SGF) comprising 40% ethanol at 37° C,  
characterized by the percent amount of active released at 0.5 hours of  
dissolution that deviates no more than about 20 % points from the  
corresponding in-vitro dissolution rate measured in a USP Apparatus 1  
(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF)  
20 at 37° C without ethanol, using a flattened and non flattened reference tablet  
or flattened and non flattened reference multi particulates, respectively.

[0011] In certain embodiments, the present invention is directed to a solid oral  
extended release pharmaceutical dosage form comprising an extended release  
matrix formulation, the extended release matrix formulation comprising  
25 a composition comprising at least:

- (1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;  
and
- (2) at least one active agent; and

wherein the composition comprises at least about 80 % (by wt) polyethylene oxide.

5 [0012] According to certain such embodiments the active agent is oxycodone hydrochloride and the composition comprises more than about 5% (by wt) of the oxycodone hydrochloride.

10 [0013] In certain embodiments, the present invention is directed to a solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprising a composition comprising at least:

- (1) at least one active agent;
- (2) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
- 15 and
- (3) at least one polyethylene oxide having, based on rheological measurements, a molecular weight of less than 1,000,000.

20 [0014] In certain embodiments, the present invention is directed to a process of preparing a solid oral extended release pharmaceutical dosage form, comprising at least the steps of:

- (a) combining at least
  - (1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000, and
  - 25 (2) at least one active agent,to form a composition;
- (b) shaping the composition to form an extended release matrix formulation; and

(c) curing said extended release matrix formulation comprising at least a curing step of subjecting the extended release matrix formulation to a temperature which is at least the softening temperature of said polyethylene oxide for a time period of at least about 1 minute.

5

[0015] In certain embodiments, the present invention is directed to a process of preparing a solid oral extended release pharmaceutical dosage form, comprising at least the steps of:

(a) combining at least

10

(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000, and

(2) at least one active agent, to form a composition;

15

(b) shaping the composition to form an extended release matrix formulation; and

(c) curing said extended release matrix formulation comprising at least a curing step wherein said polyethylene oxide at least partially melts.

20

[0016] In certain embodiments, the present invention is directed to a solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation comprising an active agent in the form of a tablet or multi particulates,

25

wherein the tablet or the individual multi particulates can at least be flattened without breaking, characterized by a thickness of the tablet or of the individual multi particulate after the flattening which corresponds to no more than about 60 % of the thickness of the tablet or the individual multi particulate before flattening, and wherein said flattened tablet or the flattened multi particulates provide an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent

30

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.